Search results
Results from the WOW.Com Content Network
At 52 weeks after successful withdrawal, a 22% improvement in cognitive status was found, as well as improved social functioning. Those who remained on benzodiazepines experienced a 5% decline in cognitive abilities, which seemed to be faster than that seen in normal aging, suggesting the longer the intake of benzodiazepines, the worse the ...
For example, in an MDMA ("ecstasy" and "molly") comedown, if the user experiences severe, persisting emotional distress, such as panic attacks, severe generalized anxiety, or insomnia following an MDMA session, a physician may prescribe a benzodiazepine (specifically, lorazepam) and/or sleep aid (e.g., zolpidem), to alleviate those effects.
Olanzapine, sold under the brand name Zyprexa among others, is an atypical antipsychotic primarily used to treat schizophrenia and bipolar disorder. [13] It is also sometimes used off-label for treatment of chemotherapy-induced nausea and vomiting [ 14 ] and as an appetite stimulant . [ 15 ]
Specifically, studies suggest that muscle loss with GLP-1s can range from 25 to 39 percent of the total weight loss while muscle loss via caloric restriction (with less total weight loss) ranges ...
2. Eat Smaller, More Frequent Meals. Instead of three main meals, try eating smaller, more frequent meals throughout the day. This can help if nausea is making it hard to feel like eating or if ...
New research suggests that slowly tapering off GLP-1 drugs like Ozempic and Wegovy while adopting lifestyle changes may help prevent rebound weight gain.
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...
Eli Lilly’s weight loss drug Zepbound is no longer in short supply, the FDA said, worrying patients who use cheaper, off-brand versions of the drug. On Thursday, Dec. 19, the U.S. Food and Drug ...